Prosecution Insights
Last updated: April 19, 2026
Application No. 18/794,403

Electrostatic Printing of Cyclodextrin Compositions

Non-Final OA §102
Filed
Aug 05, 2024
Examiner
DIAMOND, ALAN D
Art Unit
3991
Tech Center
3900
Assignee
Verdant Technologies LLC
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
2y 5m
To Grant
79%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
137 granted / 192 resolved
+11.4% vs TC avg
Moderate +8% lift
Without
With
+7.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
21 currently pending
Career history
213
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
22.9%
-17.1% vs TC avg
§102
6.0%
-34.0% vs TC avg
§112
35.0%
-5.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 192 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Bauman Type Continuation Application The present application, Serial No. 18/794,403 (“the ‘403 application”), was filed under 35 U.S.C. 111 as a utility application, i.e., a Bauman continuation, of application No. 18/634,437, which is a Bauman continuation of reissue application No. 17/400,758, filed 08/12/2021, which is a reissue of application No. 15/208,040, filed 07/12/2016, now U.S. Patent No. 10,376,472, which issued to Wood et al on 08/13/2019. Application No. 15/208,040 is a continuation of application No. 14/748,456, filed 06/24/2015, now U.S. Patent No. 9,421,793. The present application was filed on 08/05/2024 without any indicia that it was intended to be a continuation reissue. Likewise, 18/634,437 was filed without any indicia that it was intended to be a reissue continuation. Indicia that a continuing reissue application was filed are, as per MPEP 1451: 1. A 37 CFR 1.175 reissue oath/declaration, which is not merely a copy of the parent’s reissue oath/declaration. 2. A specification and/or claims in proper double column reissue format per 37 CFR 1.173. 3. Amendments in proper format per 37 CFR 1.173. 4. A 37 CFR 3.73 statement of assignee ownership and consent by assignee. 5. A correct transmittal letter identify the application as a reissue filing under 35 U.S.C. 251. 6. An identification of the application as being “a reissue continuation of application No. 17/400,758” or “a continuation of application number 17/400,758 and an application for reissue of patent number 10,376,472" or equivalent language. Since the present application and 18/634,437 were filed without any of said indicia, the present application is a Bauman type continuation. The claims in a Bauman type continuation application will not have the same effective U.S. filing date as the original patent. This is because a reissue application is necessarily filed after the patenting of the original application. Therefore, a Bauman type continuation application does not satisfy the copendency requirement of 35 U.S.C. 102 with respect to the original patent. Accordingly, the earliest possible effective U.S. filing date of the present application is the 08/12/2021 filing date of the earlier 17/400,758 reissue application. See In re Bauman, 683 F.2d 405, 214 USPQ 585 (CCPA 1982). See also MPEP 1451. 35 U.S.C. §102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 47-66 are rejected under 35 U.S.C. 102(a)(1) as being clearly anticipated by U.S. Patent 10,376,472 to Wood et al (hereinafter “Wood”). Wood’s specification and the instant specification disclose identical inventions. Accordingly, Wood teaches all the limitations of the instant claims and thus, anticipates claims 47-66. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALAN D DIAMOND whose telephone number is (571)272-1338. The examiner can normally be reached Monday through Thursday 5:30 am to 3:00 pm, and Fridays from 5:30 am to 9:30 am. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Patricia Engle can be reached on 571-272-6660. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Signed: /ALAN D DIAMOND/Patent Reexamination Specialist Central Reexamination Unit 3991 Conferees: /JOSEPH R KOSACK/ /Patricia L Engle/Patent Reexamination Specialist SPRS, Art Unit 3991 Central Reexamination Unit 3991
Read full office action

Prosecution Timeline

Aug 05, 2024
Application Filed
Jun 18, 2025
Response after Non-Final Action
Mar 12, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent RE50811
Rapid Imaging Systems and Methods for Facilitating Rapid Radiation Therapies
2y 5m to grant Granted Mar 10, 2026
Patent RE50805
SINGLE-LAYER ORAL DOSE OF NEURO-ATTENUATING KETAMINE
2y 5m to grant Granted Feb 24, 2026
Patent RE50799
JAK1 SELECTIVE INHIBITORS AND USES THEREOF
2y 5m to grant Granted Feb 17, 2026
Patent RE50790
INK COMPOSITION, INK JET RECORDING METHOD, METHOD FOR PRODUCING PLANOGRAPHIC PRINTING PLATE AND PLANOGRAPHIC PRINTING PLATE
2y 5m to grant Granted Feb 10, 2026
Patent RE50776
INHIBITORS OF CYCLIN-DEPENDENT KINASES
2y 5m to grant Granted Feb 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
79%
With Interview (+7.6%)
2y 5m
Median Time to Grant
Low
PTA Risk
Based on 192 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month